Upon Agamree's commercial launch in Q1 of 2024, the company aims to start a comprehensive patient “Assistance Program” to ensure affordable access for all DMD Patients, minimizing patient co ...

Catalyst Pharmaceuticals, Inc. AGAMREE ® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older. Catalyst Holds the Exclusive North American License to ...

AGAMREE previously received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023.

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that ...

Agamree is supplied as a 40mg/mL oral suspension. The product is expected to be available in the first quarter of 2024. Prior to starting treatment, all age-appropriate immunizations should be ...

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy inpatients aged 4 years and older This approval makes AGAMREE the ...

Agamree oral suspension 40 mg/mL is now commercially available in the United States for the treatment of Duchenne muscular dystrophy in patients aged 2 years and older, according to a press release.

Agamree stands out due to its unique mechanism of action, which involves targeting glucocorticoid and mineralocorticoid receptors with a differential effect and modifying downstream activity, ...

(RTTNews) - Santhera Pharmaceuticals said that it received positive recommendation from the Scottish Medicines Consortium for use of AGAMREE (Vamorolone) within NHS Scotland for the treatment of ...

Santhera Pharmaceuticals has received the Food and Drug Administration’s blessing for Agamree (vamorolone) oral suspension 40 mg/ml for the treatment of Duchenne muscular dystrophy in patients 2 ...

AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare ...

Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE ...